Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model

Journal of Controlled Release

Volumn 182, Issue 1, 2014, Pages 90-96

  Zhang, Jing ^a,b   Miao, Lei ^a   Guo, Shutao ^a   Zhang, Yuan ^a   Zhang, Lu ^a   Satterlee, Andrew ^a   Kim, William Y ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Bladder cancer; Cisplatin; Gemcitabine; Stroma; Tumor associated fibroblasts

Indexed keywords

CELL CULTURE; CELL DEATH; DRUG PRODUCTS; FIBROBLASTS; NANOPARTICLES; TUMORS;

ANTINEOPLASTIC EFFECT; BLADDER CANCERS; CIS-PLATIN; GEMCITABINE; INHIBITORY EFFECT; MULTIPLE INJECTIONS; STROMA; SYNERGISTIC EFFECT;

PLATINUM COMPOUNDS;

ALPHA SMOOTH MUSCLE ACTIN; CISPLATIN; COLLAGEN; EVANS BLUE; GEMCITABINE; GEMCITABINE MONOPHOSPHATE; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG POTENTIATION; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER TOXICITY; MOUSE; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; STROMA; TUMOR XENOGRAFT; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; FEMALE; METABOLISM; NUDE MOUSE; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; FIBROBLASTS; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; NIH 3T3 CELLS; URINARY BLADDER NEOPLASMS;

EID: 84897385973     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.03.016     Document Type: Article

References (39)

1. M. Grasso Bladder cancer: a major public health issue Eur. Urol. 7 2008 510 515
2. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck, J.A. Witjes, C. Bouffioux, L. Denis, D.W. Newling, and K. Kurth Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur. Urol. 49 2006 466 475 (Pubitemid 43259554)
3. B. Parada, F. Reis, R. Cerejo, P. Garrido, J. Sereno, M. Xavier-Cunha, P. Neto, A. Mota, A. Figueiredo, and F. Teixeira Omega-3 fatty acids inhibit tumor growth in a rat model of bladder cancer Biomed. Res. Int. 2013 10.1155/2013/368178
4. D. Cosco, D. Paolino, F. Cilurzo, F. Casale, and M. Fresta Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases Int. J. Pharm. 17 2012 229 237
5. A.A. Gabizon, H. Shmeeda, and S. Zalipsky Pros and cons of the liposome platform in cancer drug targeting J. Liposome Res. 16 2006 175 183 (Pubitemid 44358991)
6. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
7. A. Albini, and M.B. Sporn The tumour microenvironment as a target for chemoprevention Nat. Rev. Cancer 7 2007 139 147 (Pubitemid 46160989)
8. J. Zhang, and J.S. Liu Tumor stroma as targets for cancer therapy Pharmacol. Ther. 137 2013 200 215
9. K. Pietras, and A. Östman Hallmarks of cancer: interactions with the tumor stroma Exp. Cell Res. 316 2010 1324 1331
10. M.M. Mueller, and N.E. Fusenig Friends or foes - bipolar effects of the tumour stroma in cancer Nat. Rev. Cancer 4 2004 839 849 (Pubitemid 39472951)
11. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. Mclntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, K.K. Frese, G. Denicola, C. Feig, C. Combs, S.P. Winter, H. Ireland-Zecchini, S. Reichelt, W.J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S.R. Hingorani, P. Huang, S.E. Davies, W. Plunkett, M. Egorin, R.H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, and D.A. Tuveson Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
12. T.A. Gonda, A. Varro, T.C. Wang, and B. Tycko Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin. Cell Dev. Biol. 21 2010 2 10
13. A. Alexa, F. Baderca, R. Lighezan, and D. Izvernariu Myofibroblasts reaction in urothelial carcinomas Rom. J. Morphol. Embryol. 50 2009 639 643
14. D. Jacob, J. Davis, and B.L. Fang Xenografitic tumor models in mice for cancer research, a technical review Gene Ther. Mol. Biol. 18 2004 213 219
15. R.E. Hurst, P.J. Hauser, K.D. Kyker, J.E. Heinlen, J.P. Hodde, M.C. Hiles, S.D. Kosanke, M. Dozmorov, and M.A. Ihnat Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy" PLoS ONE 8 2013 1 10
16. Y. Zhang, N.M. Schwerbrock, A.B. Rogers, W.Y. Kim, and L. Huang Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC Mol. Ther. 21 2013 1559 1569
17. S.T. Guo, Y.H. Wang, L. Miao, Z.H. Xu, C.M. Lin, Y. Zhang, and L. Huang Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy ACS Nano 7 2013 9896 9904
18. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
19. Y. Han, Z. He, A. Schulz, T.K. Bronich, R. Jordan, R. Luxenhofer, and A.V. Kabanov Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles Mol. Pharm. 9 2012 2302 2313
20. C. Bornmann, R. Graeser, N. Esser, V. Ziroli, P. Jantscheff, T. Keck, C. Unger, U.T. Hopt, U. Adam, C. Schaechtele, U. Massing, and E. von Dobschuetz A new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging Cancer Chemother. Pharmacol. 61 2008 395 405 (Pubitemid 350275974)
21. J. Li, Y. Yang, and L. Huang Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor J. Control. Release 158 2012 108 114
22. G.J. Peters, C.J. Van Moorsel, B. Lakerveld, K. Smid, P. Noordhuis, E.C. Comijn, D. Weaver, J.C. Willey, D. Voorn, W.J. Van der Vijgh, and H.M. Pinedo Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines Int. J. Oncol. 28 2006 237 244
23. O.G. Besançon, G.A. Tytgat, R. Meinsma, R. Leen, J. Hoebink, G.V. Kalayda, U. Jaehde, H.N. Caron, and A.B. van Kuilenburg Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids Cancer Lett. 319 2012 23 30
24. M.D. Walsh, S.K. Hanna, J. Sen, S. Rawal, C.B. Cabral, A.V. Yurkovetskiy, R.J. Fram, T.B. Lowinger, and W.C. Zamboni Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts Clin. Cancer Res. 18 2012 2591 2602
25. K. Greish Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines J. Drug Target. 15 2007 457 464 (Pubitemid 47209047)
26. S.D. Li, and L. Huang Nanoparticles evading the reticuloendothelial system: role of the supported bilayer Biochim. Biophys. Acta 1788 2009 2259 2266
27. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
28. R. Banerjee, P. Tyagi, S. Li, and L. Huang Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells Int. J. Cancer 112 2004 693 700 (Pubitemid 39425952)
29. L.D. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E.C. Ramsay, M.B. Bally, and A.S. Janoff Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 5 2006 1854 1863 (Pubitemid 44323254)
30. J. Liu, S. Liao, B. Diop-Frimpong, W. Chen, S. Goel, K. Naxerova, M. Ancukiewicz, Y. Boucher, R.K. Jain, and L. Xu TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma Proc. Natl. Acad. Sci. U. S. A. 109 2012 16618 16623
31. M. Shimoda, K.T. Mellody, and A. Orimo Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression Semin. Cell Dev. Biol. 21 2010 19 25
32. S.H. Jang, M.G. Wientjes, and J.L. Au Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule J. Pharmacol. Exp. Ther. 296 2001 1035 1042 (Pubitemid 32187379)
33. D. Lu, M.G. Wientjes, Z. Lu, and J.L. Au Tumor priming enhances delivery and efficacy of nanomedicines J. Pharmacol. Exp. Ther. 322 2007 80 88 (Pubitemid 46956353)
34. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844 (Pubitemid 23132159)
35. K. Kuwahara, T. Sasaki, K. Kobayashi, B. Noma, M. Serikawa, T. Liboshi, H. Miyata, Y. Kuwada, M. Murakami, S. Yamasaki, K. Kariya, K. Morinaka, and K. Chayama Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites Oncol. Rep. 11 2004 73 80
36. R. Ikeda, L.C. Vermeulen, Z. Jiang, E. Lau, and J.M. Koledar Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells Exp. Ther. Med. 1 2010 853 857
37. A. Dimou, K.N. Syrigos, and M.W. Saif Overcoming the stromal barrier: technologies to optimized drug delivery in pancreatic cancer Ther. Adv. Med. Oncol. 4 2012 271 279
38. NCCN Clinical Practice Guidelines in Oncology: Bladder, Cancer. v. 1.2013.
39. A. Dash, J.A. Pettus IV, H.W. Herr, B.H. Bochner, G. Dalbagni, S.M. Donat, P. Russo, M.G. Boyle, M.I. Milowsky, and D.F. Bajorin A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 2008 2471 2477